Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: WTDEC who wrote (23114)	7/13/1998 12:58:00 PM
From: Henry Niman	Respond to of 32384

Walter, LGND's price is starting to respond. Although some seem have missed LGND breaking into the "teens" on Friday, the price has moved to 13 1/4 which is as high as it has been since last month. Volume has been on the light side and Biotechs have been out of favor for some time, but LGND continues to deliver and it's beginning to look like they may have two products for sale by te end of this year. Their progress has been stellar (although its hard to tell from the comments of investors who have become inpatient or disappointed, but it's hard to time Biotechs and they can make rather sharp moves over a short time frame). LGND should soon be getting the attention that it deserves, and those on the sidelines may be a bit surprised by how far it can go over a short time frame.

To: WTDEC who wrote (23114)	7/13/1998 1:04:00 PM
From: tonyt	Read Replies (1) \| Respond to of 32384

"those on the sidelines" shouldn't be too suprised at how far LGND can go since it has fallen over 30% over a very short period of time.

To: WTDEC who wrote (23114)	7/13/1998 1:05:00 PM
From: Henry Niman	Read Replies (3) \| Respond to of 32384

Walter, LGND keeps in close contact with the FDA and they have a good read on what is out there and what is needed. KS still affects a significant number of people and off label use could be significant. LGND senior management is draw almost exclusively from the big pharmas and they know what it takes to get the job done. I'm not surprised that the application was given priority review. I suspect that LGND will present in September and they will work closely with the FDA to get the drug launched by the end of this year. I'm not surprised by the news and I suspect that many share my view. I few unexpected announcements and some additional coverage could do wonders for LGND's depressed price (and those "bottom fishers" may very well come up empty).

To: WTDEC who wrote (23114)	7/13/1998 1:07:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Walter, I thought that we were told that LGND was "heading for $10".